Autoimmune-Associated Livedoid Vasculopathy: Response to Immunomodulatory Therapy

Livedoid vasculopathy (LV) is a rare, chronic occlusive dermopathy causing recurrent painful ulcerations, impaired healing, and significant morbidity. Historically considered a thrombotic microangiopathy, emerging evidence suggests an autoimmune or mixed pathogenesis in some patients. We present the case of a 55-year-old woman with LV and serologic features of undifferentiated connective tissue disease (UCTD) who achieved complete, durable remission using intravenous immunoglobulin (IVIG) and hydroxychloroquine (HCQ). After 16 years of refractory disease, including failure of multiple anticoagulant, antiplatelet, and immunosuppressive regimens, her ulcers resolved completely and have not recurred for more than two years. This case underscores the need to evaluate for autoimmune features in LV, highlights IVIG as an effective treatment, and demonstrates that HCQ may serve as a valuable adjunct in refractory autoimmune-associated LV.

Authors

Institutions

Publication Details

Journal
Cureus
Published
2025-09-19
DOI
https://doi.org/10.7759/cureus.92748
Primary Topic
Systemic Lupus Erythematosus Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Autoimmune-Associated Livedoid Vasculopathy: Response to Immunomodulatory Therapy

Jenice X. Cheah, Thanda Aung
Cureus
Systemic Lupus Erythematosus Research
article

Autoimmune-Associated Livedoid Vasculopathy: Response to Immunomodulatory Therapy

Jenice X. Cheah, Thanda Aung
article en

Abstract

Livedoid vasculopathy (LV) is a rare, chronic occlusive dermopathy causing recurrent painful ulcerations, impaired healing, and significant morbidity. Historically considered a thrombotic microangiopathy, emerging evidence suggests an autoimmune or mixed pathogenesis in some patients. We present the case of a 55-year-old woman with LV and serologic features of undifferentiated connective tissue disease (UCTD) who achieved complete, durable remission using intravenous immunoglobulin (IVIG) and hydroxychloroquine (HCQ). After 16 years of refractory disease, including failure of multiple anticoagulant, antiplatelet, and immunosuppressive regimens, her ulcers resolved completely and have not recurred for more than two years. This case underscores the need to evaluate for autoimmune features in LV, highlights IVIG as an effective treatment, and demonstrates that HCQ may serve as a valuable adjunct in refractory autoimmune-associated LV.

CureusVol. 17(9)
University of California, Los Angeles (US)
Openalex Percentile: Top 62%
Systemic Lupus Erythematosus Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.